KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.261
-0.018 (-6.33%)
At close: Mar 9, 2026, 4:00 PM EDT
0.265
+0.005 (1.73%)
After-hours: Mar 9, 2026, 5:38 PM EDT
Company Description
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.
The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases.
Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
KALA BIO, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Avi Minkowitz |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States | |
| Phone | 781 996 5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119103 |
| ISIN Number | US4831192020 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. R. Kim Brazzell Ph.D. | Head of Research & Development and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 17, 2026 | EFFECT | Notice of Effectiveness |
| Feb 17, 2026 | 424B3 | Prospectus |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | D | Notice of Exempt Offering of Securities |
| Feb 10, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 6, 2026 | SCHEDULE 13D | Filing |
| Feb 5, 2026 | 8-K | Current Report |
| Feb 2, 2026 | 8-K | Current Report |